Publicaciones en colaboración con investigadores/as de University of Turin (14)

2022

  1. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Journal of Clinical Oncology, Vol. 364

2021

  1. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 801-812

2019

  1. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469

2018

  1. Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis

    JAMA Oncology, Vol. 4, Núm. 10, pp. 1389-1397

2017

  1. Second primary malignancies in multiple myeloma: An overview and IMWG consensus

    Annals of Oncology, Vol. 28, Núm. 2, pp. 228-245

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement

    Journal of Clinical Oncology, Vol. 33, Núm. 6, pp. 657-664

2014

  1. Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death

    Journal of Clinical Oncology, Vol. 32, Núm. 20, pp. 2173-2180

  2. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548

  3. New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)

    Leukemia, Vol. 28, Núm. 3, pp. 525-542

2013

  1. Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials

    Haematologica, Vol. 98, Núm. 6, pp. 980-987

  2. Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    Leukemia, Vol. 27, Núm. 4, pp. 780-791

2012

  1. Management of treatment-emergent peripheral neuropathy in multiple myeloma

    Leukemia, Vol. 26, Núm. 4, pp. 595-608

  2. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    Leukemia, Vol. 26, Núm. 1, pp. 149-157